News
Maternal health start-up Partum Health expands to Dallas

Partum Health, a Chicago-based maternal health start-up that provides interdisciplinary pregnancy and postpartum care, is expanding to Dallas.
Partum, a start-up founded in Chicago in 2021, expanded to Houston in November 2023 after raising US$3.1m in seed funding.
The company, which offers both virtually and in-home services, aims to support families through proactive care from pre-conception through early parenthood.
In the United States, more women die each year of pregnancy-related complications than in any other developed country, with the majority of those deaths happening between one week and one year of giving birth. In Texas, the need is especially acute.
A 2022 study published by the Texas Medical Association ranked the state 50th among all states in access to high-quality prenatal and maternal care, citing barriers to healthcare before and after their hospital stay as a key factor.
Moreover, a report last year by the Texas Health and Human Services Commission found that 90 per cent of the state’s pregnancy-related deaths are preventable, recommending an improvement in care coordination and access to comprehensive health services to achieve better outcomes.
Partum Health was founded with a mission to change the standard of maternal care after its founders witnessed the huge gap between the care they needed and what they actually received during their own families’ perinatal experiences.
In addition to a network of postpartum speciality providers across lactation, mental health and physical therapy, the platform offers access to dedicated care coordinators to help families make informed decisions, schedule appointments and navigate insurance.
“We built Partum to help bridge the gap in comprehensive maternal health and improve outcomes during the critical postpartum period,” said Meghan Doyle, co-founder and CEO of Partum Health.
“Our offerings are focused on preventing the most common complications of pregnancy, including perinatal mood and anxiety disorders and avoidable C-sections, among others.
“We look forward to partnering with OBs and midwives across Dallas/Fort Worth to provide wraparound, interdisciplinary care to their patients.”
To receive the Femtech World newsletter, sign up here.
Entrepreneur
Just 24 hours left to nominate your company of the year

You have until Friday to nominate your femtech company of the year.
The award is one of 10 featuring at Femtech World’s third annual awards event, which attracts entries from across the UK, EU and Europe.
The Company of the Year Award is for companies that have demonstrated exceptional leadership in tackling women’s health needs through groundbreaking products, services or platforms that are shaping the future of global femtech.
If your company is driving innovation, impact and growth in this space, this award was made for you.
About the sponsor: Femovate
The category is backed by Femovate, the global femtech incubator using design to fuel innovation across every stage of a woman’s health journey, from proactive prevention through to personalised treatment.
Femovate has invested over US$2 million in design capital, working side-by-side with founding teams to bring market-ready solutions to life.
The startups it supports have collectively raised US$120 million, launched 30 products, and secured seven FDA clearances.
Why enter?
The Femtech World Awards are free to enter.
Winners and shortlisted companies receive extensive coverage across all Femtech World platforms.
Winners will also receive a trophy and the opportunity to be featured in an interview for the publication.
Find out more about the Femtech World Award and enter here by 4pm BST on Friday 17.
Diagnosis
Women with osteoporosis face increased Alzheimer’s risk, study suggests

Women with osteoporosis may be more likely to carry a gene linked to Alzheimer’s, according to new research.
Scientists found that APOE4, the most common genetic risk factor for Alzheimer’s, can weaken bone quality in women, even when standard scans appear normal.
The study, carried out by researchers at the Buck Institute for Research on Ageing in California, US, and UC San Francisco, suggests the gene may damage bone at a microscopic level long before any visible signs.
These changes can emerge as early as midlife and remain invisible to routine imaging tests used to assess bone strength.
The findings suggest a link between Alzheimer’s risk and skeletal health and could help pave the way for earlier detection of both conditions.
Professor Birgit Schilling, a senior author of the study, said: “What makes this finding so striking is that bone quality is being compromised at a molecular level that a standard bone scan simply will not catch.
“APOE4 is quietly disrupting the very cells responsible for keeping bone strong – and it is doing this specifically in females, which mirrors what we see with Alzheimer’s disease risk.”
Doctors have long observed that people with Alzheimer’s suffer higher rates of bone fractures, while osteoporosis in women is known to be one of the earliest predictors of the disease.
Now scientists believe they may have uncovered why.
Researchers led by Dr Charles Schurman carried out a detailed analysis of proteins in aged mouse bone and found that tissue was unusually rich in molecules linked to neurological disease, including those associated with Alzheimer’s.
In particular, long-lived bone cells known as osteocytes showed elevated levels of APOE, with levels twice as high in older female mice compared with younger or male animals.
Further experiments using genetically modified mice revealed that APOE4 had a strong and sex-specific impact on both bone and brain tissue.
The disruption at the protein level was even greater in bone than in the brain.
However, the bone structure itself appeared completely normal under scans.
Instead, the gene interfered with a key maintenance process inside bone cells, preventing them from repairing microscopic channels that keep bones strong and resilient.
When this process breaks down, bones become more fragile even if they look healthy on standard imaging.
These results suggest bone cells could potentially act as early biological warning signs of cognitive decline in women carrying APOE4.
Professor Lisa Ellerby, another senior author, said: “We think targeting these cells may open a new front in preserving bone quality in this population.”
Experts say the findings highlight the need to view the body as an interconnected system rather than treating diseases in isolation.
Dementia, of which Alzheimer’s is the most common form, remains one of the UK’s biggest health challenges.
Around 900,000 people are currently living with the condition, a figure expected to rise to 1.6 million by 2040.
It is already the leading cause of death, responsible for more than 74,000 deaths each year.
News
Relaunched women’s health strategy aims to tackle ‘medical misogyny’
Events2 weeks agoThree sessions that show exactly where women’s health is heading in 2026
News4 weeks agoLuna and Kindbody partner to bring data-driven insight to women’s health and fertility care
News4 weeks agoFemtech World Awards announces deadline extension
Fertility4 weeks agoMenstruation costs £20,359 a lifetime, sparking calls for Government action
Menopause3 weeks agoCalifornia plans US$3.4m menopause care overhaul
News4 weeks agoHalogen Ventures surpasses 100 investments in female-founded startups
Menopause3 weeks agoWatchdog bans five ads for women’s heath claims
Pregnancy2 weeks agoHow NIPT has evolved and what AI NIPT means in 2026















1 Comment